Related Experiment Videos
Radiation therapy for B-cell cutaneous lymphoid hyperplasia
Robert B Taylor1, John A Fortney, Ross B Pollack
1Department of Radiation Oncology, Medical University of South Carolina, Charleston, SC 29403, USA. taylorro@musc.edu
Japanese Journal of Radiology
|June 30, 2010
Summary
B-cell cutaneous lymphoid hyperplasia (BCCLH) can progress to lymphoma. Aggressive radiotherapy effectively treated a patient resistant to other therapies, showing long-term remission with manageable side effects.
Area of Science:
- Dermatology
- Oncology
- Radiation Oncology
Background:
- B-cell cutaneous lymphoid hyperplasia (BCCLH) is recognized as a pre-malignant condition within the spectrum of B-cell lymphoproliferative disorders.
- BCCLH can potentially progress to primary cutaneous B-cell lymphoma (CBCL), necessitating effective treatment strategies.
- Limited outcome data are available for BCCLH cases resistant to conventional therapies.
Observation:
- A case study involving a 63-year-old female patient with BCCLH is presented.
- The patient had previously undergone immunomodulatory treatment without success.
- The patient received an aggressive course of radiotherapy as a subsequent treatment option.
Findings:
- The patient was treated with 18 fractions of 6 MeV electron beam therapy, delivering 200 cGy per fraction.
- Following radiotherapy, the patient achieved a 3-year recurrence-free survival.
- Acute toxicity was observed as Radiation Therapy Oncology Group grade II skin toxicity, which resolved within one month post-treatment.
Implications:
- Definitive radiotherapy can be a viable and effective treatment for refractory B-cell cutaneous lymphoid hyperplasia.
- Aggressive radiotherapy demonstrates potential for long-term remission in BCCLH patients.
- Radiotherapy offers a manageable toxicity profile for treating BCCLH, even in treatment-resistant cases.
